Cargando…

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients

BACKGROUND: This study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD). METHODS: We identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012 to 2015. Propensity score (PS)-weighted Cox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Ting-Ting, Yu, Kuang-Hui, Kuo, Chang-Fu, Luo, Shue-Fen, Chiou, Meng-Jiun, Lan, Wen-Ching, Chen, Jung-Sheng, Tseng, Wen-Yi, Hsieh, Ao-Ho, Wang, Lian-Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751683/ https://www.ncbi.nlm.nih.gov/pubmed/31533805 http://dx.doi.org/10.1186/s13075-019-1993-9

Ejemplares similares

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study
por: Chen, Jiunn-Horng, et al.
Publicado: (2015)

Atrial Fibrillation Risk and Urate-Lowering Therapy in Patients with Gout: A Cohort Study Using a Clinical Database
por: Liu, Ching-Han, et al.
Publicado: (2022)

Risk of end-stage renal disease associated with gout: a nationwide population study
por: Yu, Kuang-Hui, et al.
Publicado: (2012)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Hyperthyroid and Hypothyroid Status Was Strongly Associated with Gout and Weakly Associated with Hyperuricaemia
por: See, Lai-Chu, et al.
Publicado: (2014)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis
por: Yin, Rulan, et al.
Publicado: (2018)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
por: Janssen, Carly A., et al.
Publicado: (2017)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study
por: Roughley, Matthew, et al.
Publicado: (2018)

Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review
por: Gill, Iqbal, et al.
Publicado: (2020)

Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
por: Kim, Sang-Hyon, et al.
Publicado: (2020)

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
por: Singh, Jasvinder A
Publicado: (2014)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
por: Christiansen, Sara Nysom, et al.
Publicado: (2020)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021)

Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus
por: Chang, Hsin-Wen, et al.
Publicado: (2019)

Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
por: Pisaniello, Huai Leng, et al.
Publicado: (2018)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout
por: Ahn, Huijeong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_60egvi6iaqh4oiiujp07i9lki9